TCT 324: In-Stent Restenosis Rates in CTO-PCI: a Call for a Hybrid Approach

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Boston Scientific Corporation</li></ul>